Krystal Biotech, Inc. Common Stock (KRYS) Stock Price
KRYSStock
$316.58+68.10%52W
Market Cap$9.37B
P/E45.75x
PEG Ratio—
Div yield—
Beta0.65
KRYS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)7.35%
Price vs S&P 500 (4W)-3.85%
VGM Score55.85
P/E Ratio (Annual)45.75x
KRYS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.91 | $1.79 | -6.50%(-$0.12) | |
| Q1 2026 | $1.42 | $1.83 | +28.97%(+$0.41) | |
| Q4 2025 | $1.61 | $1.70 | +5.81%(+$0.09) | |
| Q3 2025 | $1.12 | $2.66 | +137.04%(+$1.54) | |
| Q2 2025 | $1.44 | $1.29 | -10.15%(-$0.15) |
KRYS Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.28
4.28
4.28
4.26
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
KRYSKrystal Biotech, Inc. Common Stock | D | B | B | 21.3x | 22.6% | 94.6% | — | $316.58 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Krystal Biotech, Inc. Common Stock
Krystal Biotech is a commercial-stage biotechnology company developing genetic medicines for diseases with high unmet medical needs using its proprietary HSV-1-based gene therapy platform. The company commercializes VYJUVEK, its lead therapeutic product, across the United States, European Union, and Japan. Krystal Biotech leverages its platform to create vectors that deliver therapeutic genes to target cells with exclusive rights to develop, manufacture, and commercialize VYJUVEK globally.